Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Operating Officer | February 28, 2019 | March 04, 2019 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date February 28, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,049 |
Reported balance
After 2019-02-28 transaction · row 1
1 source rowRow 1 · 2019-02-28 · Grant · Acquired 230 · Balance 14,049 F1: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2029-02-28 | Direct | 230 |
Reported balance
After 2019-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-28 · Grant · Acquired 230 · Balance 230 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,769 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,011 · Balance 44,769 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 32,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355658 · ownership.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,769 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:30 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 1,661 | $1.87 | $3,106.07 |
DisclosureSEC source: 0001193125-26-039693 · ownership.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,758 F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:12 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 41,981 | $0.90 | $37,782.90 |
DisclosureSEC source: 0001193125-26-010625 · ownership.xml · nonDerivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,669 F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 16:56 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 15,625 | $1.28 | $20,000.00 |
DisclosureSEC source: 0001193125-25-260419 · ownership.xml · nonDerivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,688 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 23:12 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 181 | $3.87 | $700.47 |
DisclosureSEC source: 0000950170-25-020120 · ownership.xml · nonDerivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 20:03 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantStock Option (Right to Buy) · Derivative | 6,356 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-23-024634 · doc4.xml · derivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,356 Underlying: Common Stock · 6,356 shares Expires 2033-04-14 F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:30 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 230 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000920465-19-000045 · wf-form4_155173864497905.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230 Underlying: Common Stock · 230 shares Expires 2029-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:30 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 230 | $4.85 | $1,115.50 |
DisclosureSEC source: 0000920465-19-000045 · wf-form4_155173864497905.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,049 F1 · kind: These shares were acquired on 02/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 230 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000920465-19-000035 · wf-form4_155061786577689.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230 Underlying: Common Stock · 230 shares Expires 2029-02-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 230 | $5.30 | $1,219.00 |
DisclosureSEC source: 0000920465-19-000035 · wf-form4_155061786577689.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,819 F1 · kind: These shares were acquired on 02/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 1,260 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000920465-19-000030 · wf-form4_154932206002913.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Underlying: Common Stock · 1,260 shares Expires 2029-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 1,260 | $5.13 | $6,463.80 |
DisclosureSEC source: 0000920465-19-000030 · wf-form4_154932206002913.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,589 F1 · kind: These shares were acquired on 01/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:58 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000920465-19-000020 · wf-form4_154847146953735.xml · derivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:54 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 213 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0000920465-19-000016 · wf-form4_154777646703556.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213 Underlying: Common Stock · 213 shares Expires 2029-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 20:54 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 213 | $5.74 | $1,222.62 |
DisclosureSEC source: 0000920465-19-000016 · wf-form4_154777646703556.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,329 F1 · kind: These shares were acquired on 01/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $6.17 | $6,166.50 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 6 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,116 Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $6.16 | $6,156.50 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 5 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,116 Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $6.15 | $6,149.30 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 4 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,116 Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $6.17 | $6,165.70 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 3 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 484 | $6.19 | $2,995.48 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,116 Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 21:29 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 516 | $6.19 | $3,191.72 |
DisclosureSEC source: 0000920465-19-000010 · wf-form4_154708733697722.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,632 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 148 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000001 · wf-form4_154656305278028.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148 Underlying: Common Stock · 148 shares Expires 2028-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 19:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 148 | $8.02 | $1,186.29 |
DisclosureSEC source: 0000920465-19-000001 · wf-form4_154656305278028.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,116 F1 · kind: These shares were acquired on 12/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 108 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0000920465-18-000065 · wf-form4_154509645839957.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108 Underlying: Common Stock · 108 shares Expires 2028-12-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 20:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 108 | $10.88 | $1,175.04 |
DisclosureSEC source: 0000920465-18-000065 · wf-form4_154509645839957.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,968 F1 · kind: These shares were acquired on 12/14/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 96 | $0.00 Strike: $14.47 | $0.00 |
DisclosureSEC source: 0000920465-18-000060 · wf-form4_154389212646140.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96 Underlying: Common Stock · 96 shares Expires 2028-11-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:55 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 96 | $12.30 | $1,180.75 |
DisclosureSEC source: 0000920465-18-000060 · wf-form4_154389212646140.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,860 F1 · kind: These shares were acquired on 11/30/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 94 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0000920465-18-000056 · wf-form4_154266510444422.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94 Underlying: Common Stock · 94 shares Expires 2028-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 94 | $12.67 | $1,190.51 |
DisclosureSEC source: 0000920465-18-000056 · wf-form4_154266510444422.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,764 F1 · kind: These shares were acquired on 11/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:42 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 85 | $0.00 Strike: $16.30 | $0.00 |
DisclosureSEC source: 0000920465-18-000053 · wf-form4_154111934501382.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires 2028-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 20:42 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 85 | $13.86 | $1,177.68 |
DisclosureSEC source: 0000920465-18-000053 · wf-form4_154111934501382.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,670 F1 · kind: These shares were acquired on 10/31/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 85 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0000920465-18-000039 · wf-form4_153965106526864.xml · derivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires 2028-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2018 Filed Oct 15, 2018 20:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 85 | $13.81 | $1,173.85 |
DisclosureSEC source: 0000920465-18-000039 · wf-form4_153965106526864.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 F1 · kind: These shares were acquired on 10/15/2018 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $20.90 | $20,895.40 |
DisclosureSEC source: 0000920465-18-000028 · wf-form4_153481353150281.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 21:00 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $32.48 | $32,475.00 |
DisclosureSEC source: 0000920465-18-000008 · wf-form4_151978322910859.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 1,000 | $33.22 | $33,215.00 |
DisclosureSEC source: 0000920465-17-000093 · wf-form4_151458526196808.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $32.47 | $0.00 |
DisclosureSEC source: 0000920465-17-000090 · wf-form4_151458505129999.xml · derivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2027-12-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0000920465-17-000083 · wf-form4_151321722953500.xml · derivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 300 | $34.44 | $10,330.50 |
DisclosureSEC source: 0000920465-17-000036 · wf-form4_148883410562989.xml · nonDerivative · entry 3 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 300 | $34.45 | $10,333.65 |
DisclosureSEC source: 0000920465-17-000036 · wf-form4_148883410562989.xml · nonDerivative · entry 2 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | PurchaseCommon Stock | 400 | $34.49 | $13,795.60 |
DisclosureSEC source: 0000920465-17-000036 · wf-form4_148883410562989.xml · nonDerivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,900 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 18:22 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 64,100 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0000920465-17-000013 · wf-form4_148374492649477.xml · derivative · entry 1 CARVER JENNIFER · CIK 0001663163 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,100 Underlying: Common Stock · 64,100 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 64,100 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on January 4, 2018, with the remaining 48,075 shares vesting monthly thereafter over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.